JP2001527517A - 血液、ウイルス性および細胞性疾患の治療組成物 - Google Patents

血液、ウイルス性および細胞性疾患の治療組成物

Info

Publication number
JP2001527517A
JP2001527517A JP50893198A JP50893198A JP2001527517A JP 2001527517 A JP2001527517 A JP 2001527517A JP 50893198 A JP50893198 A JP 50893198A JP 50893198 A JP50893198 A JP 50893198A JP 2001527517 A JP2001527517 A JP 2001527517A
Authority
JP
Japan
Prior art keywords
acid
cells
treatment
cell
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP50893198A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001527517A5 (https=
Inventor
スーザン・ピー・ペリーネ
ダグラス・ヴィー・フォーラー
ブライアン・エフ・ホワイト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/687,671 external-priority patent/US6197743B1/en
Priority claimed from US08/687,670 external-priority patent/US5939456A/en
Application filed by Individual filed Critical Individual
Publication of JP2001527517A publication Critical patent/JP2001527517A/ja
Publication of JP2001527517A5 publication Critical patent/JP2001527517A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP50893198A 1996-07-26 1997-07-28 血液、ウイルス性および細胞性疾患の治療組成物 Pending JP2001527517A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/687,670 1996-07-26
US08/687,671 US6197743B1 (en) 1996-07-26 1996-07-26 Compositions and methods for the treatment of viral disorders
US08/687,670 US5939456A (en) 1996-07-26 1996-07-26 Pulsed administration of compositions for the treatment of blood disorders
US08/687,671 1996-07-26
PCT/US1997/012818 WO1998004290A2 (en) 1996-07-26 1997-07-28 Compositions comprising an inducing agent and an anti-viral agent for the treatment of blood, viral and cellular disorders

Publications (2)

Publication Number Publication Date
JP2001527517A true JP2001527517A (ja) 2001-12-25
JP2001527517A5 JP2001527517A5 (https=) 2005-04-07

Family

ID=27104047

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50893198A Pending JP2001527517A (ja) 1996-07-26 1997-07-28 血液、ウイルス性および細胞性疾患の治療組成物

Country Status (5)

Country Link
EP (4) EP2298350A3 (https=)
JP (1) JP2001527517A (https=)
AU (1) AU3889197A (https=)
CA (1) CA2263675C (https=)
WO (1) WO1998004290A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008099730A1 (ja) * 2007-02-14 2008-08-21 Kaneka Corporation 光学活性な２－（アロイルオキシ）プロピオン酸を用いたアミン化合物の製造方法
JP2011509253A (ja) * 2008-01-08 2011-03-24 アクセリア ファーマシューティカルズ 抗菌ペプチド系に対する作動薬
JP2022525339A (ja) * 2019-03-14 2022-05-12 ヘモシアー セラピューティクス，インコーポレイティド 有機酸血症の治療方法

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910624B1 (en) 1995-03-03 2011-03-22 The Trustees Of Boston University Compositions for the treatment of blood disorders
WO1999040883A2 (en) 1998-02-11 1999-08-19 Faller Douglas V Compositions and methods for the treatment of cystic fibrosis
WO1999048526A1 (en) * 1998-03-26 1999-09-30 Franco Lori METHOD OF RENDERING A HUMAN IMMUNODEFICIENCY VIRUS POPULATION REPLICATION INCOMPETENT $i(IN VIVO)
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
MXPA02004092A (es) * 1999-11-05 2003-02-12 Emisphere Tech Inc Compuestos y composiciones de acido fenilaminocarboxilico para administrar agentes activos.
DE10000577A1 (de) 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
GB0008966D0 (en) 2000-04-13 2000-05-31 Imp College Innovations Ltd Vectors for gene therapy
AU4317500A (en) * 2000-05-02 2001-11-12 Lead Chemical Co., Ltd. Antibiral compositions containing phorbol derivatives as the main active ingredient
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
US7157423B2 (en) 2001-01-12 2007-01-02 Fumapharm Ag Fumaric acid amides
CA2526586C (en) 2003-09-09 2010-03-16 Biogen International Gmbh The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
GB0413702D0 (en) 2004-06-18 2004-07-21 Molmed Spa Thymidine kinase
PL2316430T3 (pl) 2004-10-08 2012-11-30 Forward Pharma As Kompozycje farmaceutyczne o kontrolowanym uwalnianiu, zawierające ester kwasu fumarowego
EP1915334A2 (en) * 2005-07-07 2008-04-30 Aditech Pharma AB Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
ES2745411T3 (es) * 2006-07-27 2020-03-02 Wang Nai Fang Compuestos y composiciones de arilsulfanilo para administración de agentes activos
JP4611444B2 (ja) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
EP2680010A1 (en) 2007-02-08 2014-01-01 Biogen Idec MA Inc. Nrf2 screening assays and related methods and compositions
WO2008128299A1 (en) * 2007-04-24 2008-10-30 Murdoch Childrens Research Institute Therapeutic protocol for treating hemoglobinopathy
US20110224297A1 (en) * 2008-04-11 2011-09-15 Brown Stephen J Methods of administering prostratin and structural analogs thereof
CN102369001A (zh) 2009-01-09 2012-03-07 前进制药公司 包含溶蚀骨架中的一种或多种富马酸酯的药物制剂
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
WO2011072086A1 (en) * 2009-12-08 2011-06-16 Hemaquest Pharmaceuticals, Inc. Methods and low dose regimens for treating red blood cell disorders
WO2011113013A2 (en) 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
JP2013523795A (ja) 2010-04-06 2013-06-17 バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー 植物のストレス耐性を増強させるための４−フェニル酪酸及び／又はその塩の使用
KR101293620B1 (ko) 2011-08-19 2013-08-13 국립암센터 트랜스-스플라이싱 라이보자임 및 암치료 유전자를 포함하는 재조합 아데노바이러스 및 이의 용도
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
KR102085557B1 (ko) 2013-03-14 2020-03-06 엘커메스 파마 아일랜드 리미티드 푸마레이트의 프로드럭 및 다양한 질환을 치료하는데 있어서의 이들의 용도
JP6337135B2 (ja) 2014-02-24 2018-06-06 アルカーメス ファーマ アイルランド リミテッド フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用
JP7158104B2 (ja) 2016-07-15 2022-10-21 ビラクタ セラピューティクス，インク． Ｎｋ細胞ベースの療法で使用するためのｈｄａｃ阻害剤
WO2018140934A1 (en) * 2017-01-30 2018-08-02 The Children's Hospital Of Philadelphia Compositions and methods for hemoglobin production
WO2020033412A1 (en) * 2018-08-06 2020-02-13 Watt Richard K Compositions and methods for treating iron overload
WO2020180534A1 (en) 2019-03-01 2020-09-10 President And Fellows Of Harvard College Methods and compositions for protein delivery
AU2020283590A1 (en) 2019-05-31 2022-01-20 Viracta Subsidiary, Inc. Methods of treating virally associated cancers with histone deacetylase inhibitors
WO2022051304A1 (en) * 2020-09-01 2022-03-10 I2O Therapeutics, Inc. Ionic liquid formulations for treating diabetes
CN113621577B (zh) * 2021-08-05 2023-03-10 河南普诺易生物制品研究院有限公司 人源化hek293细胞系表达重组蛋白用培养基添加剂、重组乙肝疫苗、表达方法
AU2022386166A1 (en) 2021-11-10 2024-06-20 I2O Therapeutics, Inc. Ionic liquid compositions
CN120241679B (zh) * 2025-03-06 2025-12-05 华南农业大学 方酸类化合物在制备抗弓形虫病药物中的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5813512A (ja) * 1981-07-03 1983-01-26 シャルル・シャニ Ｃ↓１−ｃ↓６カルボン酸と塩基性アミノ酸との反応生成物を含む薬剤
EP0324574A2 (en) * 1988-01-13 1989-07-19 Arizona Board Of Regents Immunomodulating bryostatins
JPH04501123A (ja) * 1989-08-01 1992-02-27 ザ　ユニヴァーシティ　オブ　ミシガン 脱水／水補給リポソームに被嚢されたペプチド／タンパク質の局所送達
WO1993004683A1 (en) * 1991-09-12 1993-03-18 American Cyanamid Company Method of treating latent herpes viral infections
WO1995010271A2 (en) * 1993-10-12 1995-04-20 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Phenylacetate and derivatives alone or in combination with other compounds against neoplastic conditions and other disorders
WO1995011699A1 (en) * 1993-10-29 1995-05-04 The Trustees Of Boston University Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
WO1996002244A1 (en) * 1994-07-20 1996-02-01 Agis Industries (1983) Ltd. A topical preparation for the prevention and treatment of lesions and sores associated with a herpes virus

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US496525A (en) 1893-05-02 Eugene gillet de montmore
US4470970A (en) * 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US4704402A (en) 1982-06-12 1987-11-03 University Of Pittsburgh Method of treating sickle cell anemia
US4747825A (en) 1984-06-29 1988-05-31 Ferring Laboratories, Inc. Apparatus and methodology for pulsed administration of growth promoting agents
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4948592A (en) 1986-05-09 1990-08-14 Alza Corporation Pulsed drug delivery
US4723958A (en) 1986-05-23 1988-02-09 Merck & Co., Inc. Pulsatile drug delivery system
US5025029A (en) 1986-10-10 1991-06-18 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin
US4822821A (en) 1986-10-10 1989-04-18 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin
US4965251A (en) 1987-04-03 1990-10-23 The Board Of Regents Of The University Of Washington Pulse treatment of hemoglobinopathies with erythropoietin
US5032507A (en) 1987-11-13 1991-07-16 The Salk Institute For Biological Studies Potentiation of erythropoiesis
US4997815A (en) 1988-11-01 1991-03-05 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin
WO1993007866A2 (en) * 1991-10-21 1993-04-29 Dvorit Samid Compositions and methods for therapy and prevention of cancer, aids, and anemia
US5403590A (en) 1992-12-21 1995-04-04 New England Deaconess Hospital Corporation Method of pulsatile drug infusion
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5813512A (ja) * 1981-07-03 1983-01-26 シャルル・シャニ Ｃ↓１−ｃ↓６カルボン酸と塩基性アミノ酸との反応生成物を含む薬剤
EP0324574A2 (en) * 1988-01-13 1989-07-19 Arizona Board Of Regents Immunomodulating bryostatins
JPH04501123A (ja) * 1989-08-01 1992-02-27 ザ　ユニヴァーシティ　オブ　ミシガン 脱水／水補給リポソームに被嚢されたペプチド／タンパク質の局所送達
WO1993004683A1 (en) * 1991-09-12 1993-03-18 American Cyanamid Company Method of treating latent herpes viral infections
WO1995010271A2 (en) * 1993-10-12 1995-04-20 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Phenylacetate and derivatives alone or in combination with other compounds against neoplastic conditions and other disorders
WO1995011699A1 (en) * 1993-10-29 1995-05-04 The Trustees Of Boston University Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
WO1996002244A1 (en) * 1994-07-20 1996-02-01 Agis Industries (1983) Ltd. A topical preparation for the prevention and treatment of lesions and sores associated with a herpes virus

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN6007004548, Ｐｒｏｃｅｅｄｉｎｇｓ． Ａｎｎｕａｌ Ｍｅｅｔｉｎｇ ｏｆ ｔｈｅ Ａｍｅｒｉｃａｎ Ａｓｓｏｃｉ, 19960423, Ｖｏｌ．３７, ｐ４１１−４１２ *
JPN6009026838, Ｎｅｗ Ｅｎｇｌａｎｄ Ｊｏｕｒｎａｌ ｏｆ Ｍｅｄｉｃｉｎｅ, 1993, Ｖｏｌ．３２８，Ｎｏ．２, ｐ８１−８６ *
JPN6009026839, Ｂｌｏｏｄ, 1995, Ｖｏｌ．８５，Ｎｏ．１, ｐ４３−４９ *
JPN6009026841, Ｂｌｏｏｄ, 1994, Ｖｏｌ．８４，Ｎｏ．１, ｐ３３９−３４３ *
JPN6009026843, Ｂｌｏｏｄ, 1993, Ｖｏｌ．８２，Ｎｏ．７, ｐ２２０３−２２０９ *
JPN6009026845, Ｂｌｏｏｄ, 1994, Ｖｏｌ．８４，Ｎｏ．９, ｐ３１９８−３２０４ *
JPN6009026847, Ｂｌｏｏｄ, 1989, Ｖｏｌ．７４，Ｎｏ．６, ｐ１９６３−１９７１ *
JPN6009026849, Ｂｌｏｏｄ, 1988, Ｖｏｌ．７２，Ｎｏ．６, ｐ１９６１−１９６７ *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008099730A1 (ja) * 2007-02-14 2008-08-21 Kaneka Corporation 光学活性な２－（アロイルオキシ）プロピオン酸を用いたアミン化合物の製造方法
JP2011509253A (ja) * 2008-01-08 2011-03-24 アクセリア ファーマシューティカルズ 抗菌ペプチド系に対する作動薬
JP2022525339A (ja) * 2019-03-14 2022-05-12 ヘモシアー セラピューティクス，インコーポレイティド 有機酸血症の治療方法

Also Published As

Publication number Publication date
AU3889197A (en) 1998-02-20
EP0969869A2 (en) 2000-01-12
EP2298350A2 (en) 2011-03-23
EP1886677A1 (en) 2008-02-13
EP2298350A3 (en) 2011-06-08
EP1611885A1 (en) 2006-01-04
CA2263675A1 (en) 1998-02-05
EP1611885A8 (en) 2007-10-24
WO1998004290A2 (en) 1998-02-05
WO1998004290A3 (en) 1998-08-13
CA2263675C (en) 2010-04-13

Similar Documents

Publication Publication Date Title
JP2001527517A (ja) 血液、ウイルス性および細胞性疾患の治療組成物
US6011000A (en) Compositions for the treatment of blood disorders
JP6759402B2 (ja) Ｆｌｔ３変異を有する急性骨髄性白血病の治療用の医薬組成物
US20010009922A1 (en) Compositions and methods for the treatment of viral disorders
JP2021091690A (ja) 急性骨髄性白血病（ａｍｌ）のための新規併用治療
US20090082444A1 (en) Compositions for the Treatment of Blood Disorders
WO1996027369A9 (en) Compositions for the treatment of blood disorders
US20260009081A1 (en) Clonal hematopoiesis and cytokine targets
Bergamini et al. Enhanced production of tumor necrosis factor-α and interleukin-6 due to prolonged response to lipopolysaccharide in human macrophages infected in vitro with human immunodeficiency virus type 1
Liu et al. Regulation of S100A4 expression via the JAK2–STAT3 pathway in rhomboid-phenotype pulmonary arterial smooth muscle cells exposure to hypoxia
Oberdörfer et al. Role of IDO activation in anti-microbial defense in human native astrocytes
WO2017161307A1 (en) Indole regulation of antigen presenting cells
JP2006503871A (ja) Ａｍｌの処置
US20240216320A1 (en) Compositions and methods for treating sickle cell disease
JP2020504164A (ja) 急性骨髄性白血病の予防および処置
US20010053772A1 (en) Aza analogues of alkyl lysophospholipids exert immunomodulatory effects
JP2024096939A (ja) 骨髄増殖性障害を患う患者の処置のための方法及び医薬組成物
CN104902900A (zh) 使用cbp/连环蛋白的抑制剂治疗病毒性和传染性疾病
JP4014330B2 (ja) ウイルス感染防御剤
CN1897973B (zh) 乳铁蛋白和聚肌胞苷酸在制备动物自然杀伤细胞的增殖剂组合物中的应用
US7910624B1 (en) Compositions for the treatment of blood disorders
WO2025183089A1 (ja) 潜伏感染しているｈｉｖを再活性化するための組成物
WO2022080249A1 (ja) 炎症性腸疾患の予防又は改善剤
WO2025184298A1 (en) Combination therapy with venetoclax and zotatifin for the treatment of cancer
CN112972453B (zh) MDL-800在制备抑制SARS-CoV-2病毒易感性药物中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080205

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090609

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090908

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100803